We selected one RTK, ALK, for subsequent studies, as the gene encoding for ALK was identified as a major familial neuroblastoma predisposition gene [19] and can be targeted by US Food and Drug Administration (FDA)-approved drugs. The gene discussed is ALK; the disease is neuroblastoma.